Stryker Co. (NYSE:SYK) Holdings Trimmed by Fundsmith LLP

Fundsmith LLP reduced its position in Stryker Co. (NYSE:SYK - Free Report) by 0.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,333,977 shares of the medical technology company's stock after selling 2,844 shares during the period. Stryker comprises approximately 8.2% of Fundsmith LLP's holdings, making the stock its 3rd largest position. Fundsmith LLP owned approximately 1.40% of Stryker worth $1,920,498,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. J. W. Coons Advisors LLC raised its position in Stryker by 0.7% in the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after buying an additional 26 shares during the last quarter. Mascoma Wealth Management LLC increased its position in shares of Stryker by 22.7% during the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after purchasing an additional 27 shares during the last quarter. Opal Wealth Advisors LLC increased its position in shares of Stryker by 1.6% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock valued at $654,000 after purchasing an additional 28 shares during the last quarter. Lindbrook Capital LLC increased its position in shares of Stryker by 2.0% during the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after purchasing an additional 28 shares during the last quarter. Finally, Alhambra Investment Management LLC increased its position in shares of Stryker by 1.5% during the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company's stock valued at $719,000 after purchasing an additional 29 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the transaction, the director now directly owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. This represents a 14.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on SYK shares. BTIG Research set a $403.00 price target on shares of Stryker and gave the company a "buy" rating in a research report on Monday, April 14th. Stifel Nicolaus upped their price target on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Citigroup reaffirmed a "buy" rating and set a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. Argus set a $450.00 price target on shares of Stryker in a research report on Monday, February 3rd. Finally, JMP Securities reiterated a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $427.05.

Stryker Price Performance

SYK stock traded down $1.59 during midday trading on Friday, hitting $380.87. The company's stock had a trading volume of 758,784 shares, compared to its average volume of 1,356,009. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $145.37 billion, a price-to-earnings ratio of 49.08, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company has a 50 day moving average of $365.47 and a two-hundred day moving average of $374.48.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same period in the prior year, the company posted $2.50 EPS. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. On average, analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker's payout ratio is 45.41%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.